X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs ORCHID PHARMA LTD - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB ORCHID PHARMA LTD DR. REDDYS LAB/
ORCHID PHARMA LTD
 
P/E (TTM) x 29.7 0.1 20,406.2% View Chart
P/BV x 3.2 0.2 1,847.8% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 DR. REDDYS LAB   ORCHID PHARMA LTD
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
ORCHID PHARMA LTD
Sep-13
DR. REDDYS LAB/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs2,788194 1,437.1%   
Low Rs1,90235 5,433.4%   
Sales per share (Unadj.) Rs860.8276.5 311.3%  
Earnings per share (Unadj.) Rs57.1-79.2 -72.0%  
Cash flow per share (Unadj.) Rs122.0-43.5 -280.8%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs757.753.9 1,404.8%  
Shares outstanding (eoy) m165.9170.45 235.5%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.70.4 657.8%   
Avg P/E ratio x41.1-1.4 -2,842.5%  
P/CF ratio (eoy) x19.2-2.6 -729.4%  
Price / Book Value ratio x3.12.1 145.8%  
Dividend payout %35.00-   
Avg Mkt Cap Rs m389,0348,067 4,822.8%   
No. of employees `00023.52.8 840.1%   
Total wages/salary Rs m32,1492,527 1,272.2%   
Avg. sales/employee Rs Th6,070.86,956.1 87.3%   
Avg. wages/employee Rs Th1,366.6902.5 151.4%   
Avg. net profit/employee Rs Th402.5-1,993.0 -20.2%   
INCOME DATA
Net Sales Rs m142,81019,477 733.2%  
Other income Rs m1,552407 381.1%   
Total revenues Rs m144,36219,884 726.0%   
Gross profit Rs m23,5121,103 2,132.4%  
Depreciation Rs m10,7722,519 427.6%   
Interest Rs m7885,227 15.1%   
Profit before tax Rs m13,504-6,236 -216.5%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m4,380-125 -3,498.4%   
Profit after tax Rs m9,468-5,580 -169.7%  
Gross profit margin %16.55.7 290.8%  
Effective tax rate %32.42.0 1,615.6%   
Net profit margin %6.6-28.7 -23.1%  
BALANCE SHEET DATA
Current assets Rs m104,98411,014 953.2%   
Current liabilities Rs m68,93832,060 215.0%   
Net working cap to sales %25.2-108.1 -23.4%  
Current ratio x1.50.3 443.3%  
Inventory Days Days7495 78.4%  
Debtors Days Days10434 308.7%  
Net fixed assets Rs m104,38529,440 354.6%   
Share capital Rs m830705 117.8%   
"Free" reserves Rs m124,8862,043 6,114.1%   
Net worth Rs m125,7163,800 3,308.4%   
Long term debt Rs m25,0899,018 278.2%   
Total assets Rs m225,44346,510 484.7%  
Interest coverage x18.1-0.2 -9,391.6%   
Debt to equity ratio x0.22.4 8.4%  
Sales to assets ratio x0.60.4 151.3%   
Return on assets %4.5-0.8 -598.6%  
Return on equity %7.5-146.9 -5.1%  
Return on capital %9.7-3.7 -259.9%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m72,6237,513 966.6%   
Fx outflow Rs m18,9165,649 334.9%   
Net fx Rs m53,7071,865 2,880.5%   
CASH FLOW
From Operations Rs m18,0301,682 1,072.1%  
From Investments Rs m-14,883-9,860 150.9%  
From Financial Activity Rs m-4,4406,644 -66.8%  
Net Cashflow Rs m-1,236-1,535 80.5%  

Share Holding

Indian Promoters % 25.5 32.3 78.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 4.6 117.4%  
FIIs % 35.3 3.3 1,069.7%  
ADR/GDR % 18.5 4.6 402.2%  
Free float % 15.3 55.3 27.7%  
Shareholders   75,885 84,811 89.5%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Healthcare and Power Stocks Witness Buying(Closing)

Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 21, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS